Novartis says Rapsido safety profile consistent; no routine lab monitoring
Novartis (NVS) says Rhapsido’s safety profile in the SD remains consistent with CSU, and that no routine lab monitoring is required.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.